Controlant

Name: Controlant
Brand: Controlant

Controlant provides real-time cold chain and pharmaceutical supply chain visibility through IoT monitoring devices, the Aurora cloud platform, and a 24/7/365 managed monitoring and response service.

Est 2007|Valuation $144.5M|Raised $219M|5 Ref Customers

LinkedIn 10K|Web traffic 14K|FTEs 248

MarketsSupply Chain Visibility

Published Oct 1, 2026

01Common complaints

- Budget-constrained programs for low-value goods where single-use passive loggers are sufficiently compliant and more cost-effective. - Organizations without the operational capacity to respond to alerts; an in-transit visibility solution requires procedures and staffing to realize value. - Procurement processes that demand publicly published standard pricing for vendor evaluation and internal cost modeling. - Organizations that require extensive independent customer-review validation as part of vendor selection; public user-review coverage for this vendor is limited. - Risk-averse buyers concerned about vendor operational stability should perform enhanced diligence on support SLAs, account-team continuity, and product-roadmap commitments given public employee sentiment signals.

Deal disqualifiers (poor fit)

- Programs that only require low-cost, passive logging where real-time response is not justified - Organizations without processes to operationalize in-transit alerts and interventions - Lanes with persistent connectivity constraints that prevent reliable live telemetry - Procurement processes that require publicly published standard pricing for vendor comparison - Buyers requiring extensive third-party review coverage for initial vendor selection (limited public user reviews available)

Known limitations from public evidence

Limited independent customer review coverage on common B2B review platforms, which reduces availability of third-party sentiment data for procurement.
Public employee reviews include recurring references to organizational change and layoffs; while not a product limitation, these items are relevant to operational and execution risk assessment.

Vendor-acknowledged limitations (public materials)

Public product pages do not comprehensively publish certain operational details such as battery life by device SKU, country coverage and roaming caveats by region, or API rate limits. Buyers should request device specification sheets, country coverage maps, and SLA definitions.

Roadmap disclosures

Public roadmap disclosures were not found in the sources reviewed. Buyers should request roadmap, feature-release cadence, and support/maintenance commitments during procurement.

02Why they buy

Differentiators with evidence

Emphasis on regulated-industry compliance capabilities and support for Part 11 / Annex 11 and GxP-related controls.
Inclusion of managed monitoring and response services as part of the commercial offering, in addition to the software platform.
A starter offering labeled as Controlant Go that is described by the vendor as a minimal-implementation on-ramp with starter devices for trialing the service.

Where competitors may have an advantage

More transparent presentation of commercial models and pricing structures by some competitors.
Broader BYOD or multi-sensor platform options offered by some vendors, which can be useful for mixed-fleet or multi-use cases.
More extensive third-party customer review coverage for some competitors, which can support procurement reference checks.

03Field reports

Review platform coverage reality check

G2: the vendor has a listing but limited customer reviews on G2 at the time of this review.
Capterra, TrustRadius, and Gartner Peer Insights listings were not located in the public sources reviewed for this report.

Community/social discussions

Public community discussion and social-media evidence of customer sentiment were limited or not easily discoverable in the searches performed for this report.

Customer stories (vendor and partner-published)

The vendor publishes customer stories and partner case narratives. One publicly referenced example involves a large global logistics provider; these case narratives provide use-case context and vendor-reported outcomes but are vendor- or partner-published material and not independently audited within the public sources reviewed.

Direct quotes (positive and negative)

Publicly visible customer quotes on independent review platforms were not available in this research run. Employee reviews on employer-review sites indicate positive and negative perspectives on internal culture, which can be a signal for operational and execution risk but do not substitute for customer satisfaction data.

Why customers may choose the vendor (inferred)

Requirement for in-transit monitoring and the ability to perform interventions during transit rather than only post-delivery data review
Need for reporting and audit trails aligned to Part 11 / Annex 11 requirements
Desire to outsource monitoring and response activity as a managed service to reduce internal staffing requirements

Why some customers might leave (inferred churn drivers)

Total cost versus simpler passive logger approaches
Lane coverage or connectivity limitations in certain geographies
Integration complexity with existing TMS/WMS/ERP systems
Support responsiveness concerns under peak volume conditions

A major global logistics provider — real-time monitoring / RTLM partnership

What is described: - Continuous oversight of pharmaceutical shipments with the ability to intervene during transit. - Vendor- and partner-published anecdote of locating a missing shipment quickly via real-time monitoring. Metrics and claims: - The case narrative includes environmental-impact claims related to reusable devices and a network-level CO2 savings assertion. Critical evaluation: - Case metrics are vendor- or partner-published and not accompanied by independent, public audit documentation. Buyers should request baseline and post-implementation KPIs, definitions of success, and playbook documentation showing how interventions are executed and measured.

Reported automated release metrics (example referenced)

Vendor-reported outcomes presented in public case materials include high rates of automated releases and reduced release times in specific customer contexts.

Critical evaluation:

These outcomes are reported in vendor-controlled materials without publicly provided methodologies, sample sizes, or timeframes. Buyers should request full case-study decks or methodology statements when evaluating similar claims.

04Best fit

Company sizes

Best fit appears to be mid-market to enterprise organizations in pharmaceutical manufacturing and global logistics where the value of real-time monitoring and managed response supports the cost of an integrated solution.

Industries / verticals

Pharmaceutical manufacturing and distribution
Clinical trial logistics
Pharma-specialist logistics providers and 3PLs

Roles and personas

Quality assurance and quality systems (release workflows, audit readiness)
Supply chain and logistics operations (exceptions and lane performance)
Cold chain and packaging engineering
IT and data governance teams for integrations and security
Control-tower teams or outsourced monitoring providers for managed monitoring

Qualification criteria (good fit)

Requirement for in-transit monitoring and the ability to intervene during transport
Requirement for reporting and audit trails aligned to Part 11 / Annex 11
Operational capability to act on alerts through SOPs and escalation paths
Desire to leverage managed monitoring/response as an extension of internal operations

05The pitch

What the product does (objective value proposition)

Controlant provides real-time cold chain and pharmaceutical supply chain visibility using: - IoT monitoring devices (temperature, location, and related condition data) - A cloud-based visibility platform (the Aurora Platform) - 24/7/365 monitoring and response services (a managed monitoring and exception-management service) The vendor presents the solution as an operational and quality/compliance tool for temperature-sensitive, regulated shipments (particularly pharmaceutical and life sciences). Claimed outcomes include reduced product loss, shorter release times, and audit-ready documentation.

Target market and positioning

Primary targets: pharmaceutical manufacturers, clinical trial supply chains, and logistics providers that specialize in pharma (3PLs and freight forwarders).
Positioning: a solution aimed at regulated industries combining real-time monitoring, workflow automation, and managed monitoring/response services rather than only passive dataloggers. The vendor contrasts in-transit intervention capabilities with passive loggers that only provide data at delivery.

Get a comprehensive analysis of Controlant including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →

Published Oct 1, 2026

01Common complaints

Budget-constrained programs for low-value goods where single-use passive loggers are sufficiently compliant and more cost-effective.
Organizations without the operational capacity to respond to alerts; an in-transit visibility solution requires procedures and staffing to realize value.
Procurement processes that demand publicly published standard pricing for vendor evaluation and internal cost modeling.
Organizations that require extensive independent customer-review validation as part of vendor selection; public user-review coverage for this vendor is limited.
Risk-averse buyers concerned about vendor operational stability should perform enhanced diligence on support SLAs, account-team continuity, and product-roadmap commitments given public employee sentiment signals.

Deal disqualifiers (poor fit)

Programs that only require low-cost, passive logging where real-time response is not justified
Organizations without processes to operationalize in-transit alerts and interventions
Lanes with persistent connectivity constraints that prevent reliable live telemetry
Procurement processes that require publicly published standard pricing for vendor comparison
Buyers requiring extensive third-party review coverage for initial vendor selection (limited public user reviews available)

Known limitations from public evidence

Limited independent customer review coverage on common B2B review platforms, which reduces availability of third-party sentiment data for procurement.
Public employee reviews include recurring references to organizational change and layoffs; while not a product limitation, these items are relevant to operational and execution risk assessment.

Vendor-acknowledged limitations (public materials)

Roadmap disclosures

Public roadmap disclosures were not found in the sources reviewed. Buyers should request roadmap, feature-release cadence, and support/maintenance commitments during procurement.

02Why they buy

Differentiators with evidence

Emphasis on regulated-industry compliance capabilities and support for Part 11 / Annex 11 and GxP-related controls.
Inclusion of managed monitoring and response services as part of the commercial offering, in addition to the software platform.
A starter offering labeled as Controlant Go that is described by the vendor as a minimal-implementation on-ramp with starter devices for trialing the service.

Where competitors may have an advantage

More transparent presentation of commercial models and pricing structures by some competitors.
Broader BYOD or multi-sensor platform options offered by some vendors, which can be useful for mixed-fleet or multi-use cases.
More extensive third-party customer review coverage for some competitors, which can support procurement reference checks.

03Field reports

Review platform coverage reality check

G2: the vendor has a listing but limited customer reviews on G2 at the time of this review.
Capterra, TrustRadius, and Gartner Peer Insights listings were not located in the public sources reviewed for this report.

Community/social discussions

Public community discussion and social-media evidence of customer sentiment were limited or not easily discoverable in the searches performed for this report.

Customer stories (vendor and partner-published)

Direct quotes (positive and negative)

Why customers may choose the vendor (inferred)

Requirement for in-transit monitoring and the ability to perform interventions during transit rather than only post-delivery data review
Need for reporting and audit trails aligned to Part 11 / Annex 11 requirements
Desire to outsource monitoring and response activity as a managed service to reduce internal staffing requirements

Why some customers might leave (inferred churn drivers)

Total cost versus simpler passive logger approaches
Lane coverage or connectivity limitations in certain geographies
Integration complexity with existing TMS/WMS/ERP systems
Support responsiveness concerns under peak volume conditions

A major global logistics provider — real-time monitoring / RTLM partnership

What is described:

Continuous oversight of pharmaceutical shipments with the ability to intervene during transit.
Vendor- and partner-published anecdote of locating a missing shipment quickly via real-time monitoring.

Metrics and claims:

The case narrative includes environmental-impact claims related to reusable devices and a network-level CO2 savings assertion.

Critical evaluation:

Case metrics are vendor- or partner-published and not accompanied by independent, public audit documentation. Buyers should request baseline and post-implementation KPIs, definitions of success, and playbook documentation showing how interventions are executed and measured.

Reported automated release metrics (example referenced)

Vendor-reported outcomes presented in public case materials include high rates of automated releases and reduced release times in specific customer contexts.

Critical evaluation:

These outcomes are reported in vendor-controlled materials without publicly provided methodologies, sample sizes, or timeframes. Buyers should request full case-study decks or methodology statements when evaluating similar claims.

04Best fit

Company sizes

Industries / verticals

Pharmaceutical manufacturing and distribution
Clinical trial logistics
Pharma-specialist logistics providers and 3PLs

Roles and personas

Quality assurance and quality systems (release workflows, audit readiness)
Supply chain and logistics operations (exceptions and lane performance)
Cold chain and packaging engineering
IT and data governance teams for integrations and security
Control-tower teams or outsourced monitoring providers for managed monitoring

Qualification criteria (good fit)

Requirement for in-transit monitoring and the ability to intervene during transport
Requirement for reporting and audit trails aligned to Part 11 / Annex 11
Operational capability to act on alerts through SOPs and escalation paths
Desire to leverage managed monitoring/response as an extension of internal operations

05The pitch

What the product does (objective value proposition)

Controlant provides real-time cold chain and pharmaceutical supply chain visibility using:

IoT monitoring devices (temperature, location, and related condition data)
A cloud-based visibility platform (the Aurora Platform)
24/7/365 monitoring and response services (a managed monitoring and exception-management service)

The vendor presents the solution as an operational and quality/compliance tool for temperature-sensitive, regulated shipments (particularly pharmaceutical and life sciences). Claimed outcomes include reduced product loss, shorter release times, and audit-ready documentation.

Target market and positioning

Primary targets: pharmaceutical manufacturers, clinical trial supply chains, and logistics providers that specialize in pharma (3PLs and freight forwarders).
Positioning: a solution aimed at regulated industries combining real-time monitoring, workflow automation, and managed monitoring/response services rather than only passive dataloggers. The vendor contrasts in-transit intervention capabilities with passive loggers that only provide data at delivery.

Get a comprehensive analysis of Controlant including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →